ערך בספרים למניה: ADMA Biologics (ADMA)

The market trend for ADMA Biologics (ADMA), whose metric reaches 1.79, serves as an indicator of the business efficiency in producing immunoglobulins. ADMA Biologics (ADMA) is developing its own plasma collection centers to increase profits while simultaneously optimizing supply chains by expanding its list of contractors. This activity possesses defensive qualities, as demand for critical therapy remains stable and independent of economic crises or seasonal fluctuations.

To minimize risks when selecting an asset, one must evaluate its intrinsic value. This indicator is calculated as the difference between total assets and liabilities, divided by the number of shares. Analyzing the actual book value per share allows for the determination of the issuer's real capital. For ADMA Biologics (ADMA), growth in this value confirms the efficiency of owning plasma collection centers. Resource capitalization through patents ensures a steady strengthening of the company's financial foundation.